<DOC>
	<DOCNO>NCT00517517</DOCNO>
	<brief_summary>The objective Phase I/II study ass safety immunogenicity two different dose level non-adjuvanted H5N1 influenza vaccine healthy young adult population . Subjects randomize 1:1 receive two intramuscular injection ( 21 day apart ) vaccine contain either 3.75 µg 7.5 µg H5N1 hemagglutinin ( HA ) antigen non-adjuvanted formulation . Subjects monitor safety antibody response vaccine . A data safety monitor board review safety data first second vaccination .</brief_summary>
	<brief_title>Safety Immunogenicity Study Two Doses Inactivated H5N1 Influenza Vaccine ( Whole Virion , Vero Cell Derived )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hemagglutinins</mesh_term>
	<criteria>Are 21 45 year age , inclusive , day screen Have understanding study , agree provision , give write informed consent prior study entry Are clinically healthy , determine Investigator 's clinical judgment collection medical history performance physical examination Are physically mentally capable participate study Agree keep daily record symptom duration study If female capable bearing child , negative urine pregnancy test result within 24 hour schedule first vaccination agree employ adequate birth control measure duration study . Have history exposure H5N1 virus history vaccination H5N1 influenza virus Are high risk contract H5N1 influenza infection ( e.g . poultry worker ) Suffer history significant neurological , cardiovascular , pulmonary ( include asthma ) , hepatic , metabolic , rheumatic , autoimmune , hematological renal disorder Suffer inherit acquired immunodeficiency Test positive Human Immunodeficiency Virus ( HIV ) , Hepatitis B Surface Antigen ( HbsAg ) Hepatitis C Virus ( HCV ) Suffer disease undergo form treatment expect influence immune response . Such treatment include , limited , systemic high dose inhale ( &gt; 800µg/day beclomethasone dipropionate equivalent ) corticosteroid , radiation treatment immunosuppressive cytotoxic drug Have history inflammatory degenerative neurological disease ( e.g . Guillain Barré syndrome ) Have history severe allergic reaction anaphylaxis Have rash , dermatologic condition tattoo may interfere injection site reaction rating Have receive blood transfusion immunoglobulin within 90 day study entry Have donate blood plasma within 30 day study entry Have receive live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study Have undergo systemic corticoid therapy within 30 day prior study entry Have functional surgical asplenia Have know suspect problem alcohol drug abuse Were administer investigational drug within six week prior study entry concurrently participate clinical study include administration investigational product Are member team conduct study dependent relationship study Investigator . Dependent relationship include close relative ( i.e. , child , partner/spouse , sibling , parent ) well employee Investigator site conduct study If female : pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Pandemic influenza</keyword>
</DOC>